Aleksandr E. Barulin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aleksandr E. Barulin has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Olga Victorovna Kurushina
Volgograd State Medical University, Ministry of Health of Russia
29 shared publications - F. I. Devlikamova
Kazan State Medical Academy
8 shared publications - Maxim V. Churyukanov
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Mikhail L. Kukushkin
Research Institute of General Pathology and Pathophysiology
7 shared publications - O. S. Davydov
Research Institute of General Pathology and Pathophysiology
7 shared publications - P. P. Kalinsky
Pacific State Medical University
6 shared publications
Latest Publications
- 14 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (9)
Pharmacological approaches to the correction of autonomic dysfunction in patients with hypertension
Hypertension is a major contributor to global cardiovascular morbidity and mortality. The autonomic nervous system is essential to homeostasis, and its dysfunction, present in 65—85% of hypertension cases, contributes to cognitive and psycho-autonomic disorders. Objective. To assess the efficacy and safety of sequential therapy with ethyl methylhydroxypyridine succinate (Mexidol, solution for injections and 125 mg tablets) in patients with autonomic dysfunction associated with hypertension. Materials and methods. This prospective, open-label, comparative study enrolled 60 patients aged 40 to 59 years with stage I—II hypertension and autonomic dysfunction (A.M. Vein score >15). The main group (n=30) received standard antihypertensive therapy plus ethyl methylhydroxypyridine succinate, administered intramuscularly for 10 days at 4.0 mL (200 mg), followed by oral administration of 125 mg three times daily for 8 weeks. The control group (n=30) received only standard therapy. Assessments included the A.M. Vein scale, Schulte test, Digital Symbol Substitution Test (DSST), 5-word test, Hospital Anxiety and Depression Scale (HADS), and Clinical Global Impression (CGI). Results. The main group exhibited a statistically significant reduction in the A.M. Vein score by the second visit (p<0.001), followed by further reduction at the third visit (p<0.001). Significant improvements in executive function, as measured by the DSST (p<0.001), and in early memory consolidation, as assessed by the 5-word test (p<0.001), were observed. The HADS scale demonstrated a pronounced anxiolytic and antidepressant effect (p<0.001). According to the CGI scale, improvement at the end of follow-up was observed in 69.5% of patients in the main group, compared to 0% in the control group (p<0.001). Conclusions. Sequential therapy with ethyl methylhydroxypyridine succinate (solution and tablets) is an effective and safe strategy for correcting autonomic, cognitive, and affective disorders in patients with hypertension and autonomic dysfunction.
- 14 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (9)
Pharmacological approaches to the correction of autonomic dysfunction in patients with hypertension
Hypertension is a major contributor to global cardiovascular morbidity and mortality. The autonomic nervous system is essential to homeostasis, and its dysfunction, present in 65—85% of hypertension cases, contributes to cognitive and psycho-autonomic disorders. Objective. To assess the efficacy and safety of sequential therapy with ethyl methylhydroxypyridine succinate (Mexidol, solution for injections and 125 mg tablets) in patients with autonomic dysfunction associated with hypertension. Materials and methods. This prospective, open-label, comparative study enrolled 60 patients aged 40 to 59 years with stage I—II hypertension and autonomic dysfunction (A.M. Vein score >15). The main group (n=30) received standard antihypertensive therapy plus ethyl methylhydroxypyridine succinate, administered intramuscularly for 10 days at 4.0 mL (200 mg), followed by oral administration of 125 mg three times daily for 8 weeks. The control group (n=30) received only standard therapy. Assessments included the A.M. Vein scale, Schulte test, Digital Symbol Substitution Test (DSST), 5-word test, Hospital Anxiety and Depression Scale (HADS), and Clinical Global Impression (CGI). Results. The main group exhibited a statistically significant reduction in the A.M. Vein score by the second visit (p<0.001), followed by further reduction at the third visit (p<0.001). Significant improvements in executive function, as measured by the DSST (p<0.001), and in early memory consolidation, as assessed by the 5-word test (p<0.001), were observed. The HADS scale demonstrated a pronounced anxiolytic and antidepressant effect (p<0.001). According to the CGI scale, improvement at the end of follow-up was observed in 69.5% of patients in the main group, compared to 0% in the control group (p<0.001). Conclusions. Sequential therapy with ethyl methylhydroxypyridine succinate (solution and tablets) is an effective and safe strategy for correcting autonomic, cognitive, and affective disorders in patients with hypertension and autonomic dysfunction.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”
In June 2025, an Expert Council of the Russian Association for the Study of Pain (RASP) was held. Specialists discussed the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of nonspecific (musculoskeletal) lower back pain. The meeting presented data from studies of efficacy and safety of aceclofenac, ketoprofen, lornoxicam, nimesulide, pelubiprofen, tenoxicam in the treatment of musculoskeletal back pain.
- 23 September 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (3)
Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”
In June 2025, an Expert Council of the Russian Association for the Study of Pain (RASP) was held. Specialists discussed the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of nonspecific (musculoskeletal) lower back pain. The meeting presented data from studies of efficacy and safety of aceclofenac, ketoprofen, lornoxicam, nimesulide, pelubiprofen, tenoxicam in the treatment of musculoskeletal back pain.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach
Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Treatment of chronic nonspecific low back pain in spinal osteoarthritis: effectiveness of Ambene Bio combined with standard therapeutic approach
Objective. To evaluate the effect of treatment with Ambene Bio on chronic nonspecific LBP and spinal OA in patients with and without central sensitivity syndrome (CSS). Material and methods. The sample consisted of 120 patients with chronic nonspecific LBP and spinal OA with and without CSS. Results. Regardless of clinically significant CSS, reduction of LBP and functional activity after combined treatment with Ambene Bio showed significant improvements compared to standard treatment. Satisfaction with treatment was significantly higher after combined therapy. Conclusion. Treatment of chronic nonspecific lower back pain and spinal osteoarthritis has a clinical advantage when standard therapy is combined with Ambene Bio, as it significantly reduces pain, improves functional activity and contributes to higher satisfaction with treatment.
- 20 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (1) , 22-30
Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis
Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.
- 20 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (1) , 22-30
Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis
Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.
- Open Access
- 17 March 2026
- Published by Publishing House ABV Press in The Clinician
- Vol. 19 (4) , 87-95
Post-stroke rehabilitation with a focus on motor and cognitive recovery
The relevance of neurorehabilitation research is determined by the high incidence of acute cerebrovascular pathologies, as well as the increasing risk of disability due to residual impairment after a stroke. Severe motor impairment in the limbs, static and gait disorders, and decreased intellectual and memory functions significantly reduce the quality of life of patients and increase the demand for rehabilitation services. The work considers the fundamental principles of neurorehabilitation: early initiation, comprehensiveness, consistency, interdisciplinary approach, and the appropriate combination of drug and non-drug therapies. The main approaches to motor rehabilitation for patients after a stroke are described in detail, and key areas for stroke recurrence prevention are highlighted. Physical rehabilitation methods include kinesitherapy, occupational therapy, gait training, mechanotherapy, neurodevelopment techniques, and motor control restoration using robotic devices based on biofeedback. Various physiotherapeutic approaches (massage, manual therapy, acupuncture, cryotherapy, magnetic and electrical stimulation technologies) are used as adjunctive methods to enhance the effectiveness of motor rehabilitation. Medicines and rehabilitation methods are presented through the prism of evidence-based medicine. Particular importance is given to the correction of cognitive disorders, since their preservation directly affects the success of recovery. Cognitive rehabilitation includes the use of external compensatory strategies, metacognitive training, environmental adaptation with scanning training and multisensory stimulation methods, speech exercises, as well as various computer programs and paper-based methods with training in concentration, rapid selection and switching of attention. The mechanism of action and proven efficacy of choline alfoscerate (Cereton), a multifunctional drug, are demonstrated; its use as part of a comprehensive rehabilitation program significantly improves patients’ cognitive state and enhances their adaptive capacity.
- 17 March 2026
- Published by Publishing House ABV Press in The Clinician
- Vol. 19 (4) , 87-95
Open AccessPost-stroke rehabilitation with a focus on motor and cognitive recovery
The relevance of neurorehabilitation research is determined by the high incidence of acute cerebrovascular pathologies, as well as the increasing risk of disability due to residual impairment after a stroke. Severe motor impairment in the limbs, static and gait disorders, and decreased intellectual and memory functions significantly reduce the quality of life of patients and increase the demand for rehabilitation services. The work considers the fundamental principles of neurorehabilitation: early initiation, comprehensiveness, consistency, interdisciplinary approach, and the appropriate combination of drug and non-drug therapies. The main approaches to motor rehabilitation for patients after a stroke are described in detail, and key areas for stroke recurrence prevention are highlighted. Physical rehabilitation methods include kinesitherapy, occupational therapy, gait training, mechanotherapy, neurodevelopment techniques, and motor control restoration using robotic devices based on biofeedback. Various physiotherapeutic approaches (massage, manual therapy, acupuncture, cryotherapy, magnetic and electrical stimulation technologies) are used as adjunctive methods to enhance the effectiveness of motor rehabilitation. Medicines and rehabilitation methods are presented through the prism of evidence-based medicine. Particular importance is given to the correction of cognitive disorders, since their preservation directly affects the success of recovery. Cognitive rehabilitation includes the use of external compensatory strategies, metacognitive training, environmental adaptation with scanning training and multisensory stimulation methods, speech exercises, as well as various computer programs and paper-based methods with training in concentration, rapid selection and switching of attention. The mechanism of action and proven efficacy of choline alfoscerate (Cereton), a multifunctional drug, are demonstrated; its use as part of a comprehensive rehabilitation program significantly improves patients’ cognitive state and enhances their adaptive capacity.
- 9 February 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (1) , 106-112
Efficacy and safety of ipidacrine (Neuromidin) in patients with diabetic polyneuropathy: results of an open-label comparative study
Objective. To assess the efficacy and safety of two ipidacrine (Neuromidin) treatment regimens-a stepwise regimen (intramuscular administration followed by oral therapy) and an oral-only regimen-in patients with type 1 or type 2 diabetes mellitus (DM) and confirmed diabetic polyneuropathy (DPN). Material and methods. In an open-label comparative study, the efficacy and safety of ipidacrine (Neuromidin) were evaluated in 90 patients with DPN receiving conventional antidiabetic therapy. Patients were assigned to three groups of 30 each: 1st — stepwise ipidacrine therapy (initial intramuscular administration followed by oral therapy); 2nd — oral ipidacrine therapy only; 3rd — control group (conventional antidiabetic therapy without ipidacrine). The treatment duration was 60 days. DPN was assessed using the Neuropathy Symptom Score (NSS), Neuropathy Disability Score (NDS), and Total Symptom Score (TSS). The intensity of neuropathic pain was evaluated using the Numeric Rating Scale (NRS). In addition, glycated hemoglobin (HbA1c), cognitive status (Mini-Mental State Examination, MMSE), and electroneuromyography of the peroneal nerve were assessed. Results. Both treatment groups demonstrated a significant improvement in DPN parameters (p<0.001). The stepwise regimen resulted in a more pronounced improvement in NSS (p=0.048). The intensity of neuropathic pain on the NRS significantly decreased in both treatment groups (p<0.001). A significant improvement in glycemic control parameters was observed in the active treatment groups. A mild but statistically significant improvement in cognitive function as assessed by MMSE was also noted (p≤0.04). Electroneuromyography showed positive dynamics in sensory fiber parameters. The safety profile was favorable in both treatment groups. Conclusion. Both ipidacrine regimens demonstrated high efficacy as part of combination therapy for DPN. The stepwise regimen likely provided a faster onset of clinical effect. The safety profile was favorable, and no serious adverse events were observed.
- 9 February 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (1) , 106-112
Efficacy and safety of ipidacrine (Neuromidin) in patients with diabetic polyneuropathy: results of an open-label comparative study
Objective. To assess the efficacy and safety of two ipidacrine (Neuromidin) treatment regimens-a stepwise regimen (intramuscular administration followed by oral therapy) and an oral-only regimen-in patients with type 1 or type 2 diabetes mellitus (DM) and confirmed diabetic polyneuropathy (DPN). Material and methods. In an open-label comparative study, the efficacy and safety of ipidacrine (Neuromidin) were evaluated in 90 patients with DPN receiving conventional antidiabetic therapy. Patients were assigned to three groups of 30 each: 1st — stepwise ipidacrine therapy (initial intramuscular administration followed by oral therapy); 2nd — oral ipidacrine therapy only; 3rd — control group (conventional antidiabetic therapy without ipidacrine). The treatment duration was 60 days. DPN was assessed using the Neuropathy Symptom Score (NSS), Neuropathy Disability Score (NDS), and Total Symptom Score (TSS). The intensity of neuropathic pain was evaluated using the Numeric Rating Scale (NRS). In addition, glycated hemoglobin (HbA1c), cognitive status (Mini-Mental State Examination, MMSE), and electroneuromyography of the peroneal nerve were assessed. Results. Both treatment groups demonstrated a significant improvement in DPN parameters (p<0.001). The stepwise regimen resulted in a more pronounced improvement in NSS (p=0.048). The intensity of neuropathic pain on the NRS significantly decreased in both treatment groups (p<0.001). A significant improvement in glycemic control parameters was observed in the active treatment groups. A mild but statistically significant improvement in cognitive function as assessed by MMSE was also noted (p≤0.04). Electroneuromyography showed positive dynamics in sensory fiber parameters. The safety profile was favorable in both treatment groups. Conclusion. Both ipidacrine regimens demonstrated high efficacy as part of combination therapy for DPN. The stepwise regimen likely provided a faster onset of clinical effect. The safety profile was favorable, and no serious adverse events were observed.
- 26 December 2025
- Published by Alfmed LLC in Medical alphabet
- No. 32
Cervicogenic headache: a modern view of diagnosis and treatment
Cervicogenic headache is a secondary headache that still leaves a number of questions in the discussions of representatives of the medical community, specialists in cephalgology. The article provides up-to-date information on the specifics of etiopathogenesis, clinical manifestations of cervicogenic headache, and features of diagnosis and treatment of this nosology.
- 26 December 2025
- Published by Alfmed LLC in Medical alphabet
- No. 32
Cervicogenic headache: a modern view of diagnosis and treatment
Cervicogenic headache is a secondary headache that still leaves a number of questions in the discussions of representatives of the medical community, specialists in cephalgology. The article provides up-to-date information on the specifics of etiopathogenesis, clinical manifestations of cervicogenic headache, and features of diagnosis and treatment of this nosology.
- 16 October 2025
- Published by Bionika Media in Therapy
- Vol. 7_2025
Diagnosis and differentiated treatment of shoulder pain
- 16 October 2025
- Published by Bionika Media in Therapy
- Vol. 7_2025
Diagnosis and differentiated treatment of shoulder pain
- Open Access
- 10 September 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (3)
Non-pharmacological Rehabilitation Methods for Parkinson's Disease with an Emphasis on Biofeedback Therapy: a Review
INTRODUCTION. Currently, Parkinson's disease is a common socially significant multisystem neurodegeneration that significantly limits the everyday, professional and social activities of patients. The clinical picture includes classic motor symptoms and many non-motor disorders, which requires an integrated approach to treatment. In recent years, it has been paid more attention to the development of rehabilitation for Parkinson's disease, primarily non-pharmacological methods. AIM. To present a literature review on the current use of non-pharmacological methods of treatment and rehabilitation for PD based on biofeedback (BFB). MATERIALS AND METHODS. An analysis of 59 literary sources was conducted on the RSCI and PubMed databases for the period 2010-2025 on the topic of non-pharmacological treatment methods for PD, as well as the use of rehabilitation methods with biofeedback (BFB). Data of our own clinical study are presented. RESULTS AND DISCUSSION. The review considers various options of motor rehabilitation in Parkinson's disease (strength exercises, aerobic training, methods using biofeedback, virtual reality, computer games, mental images), physiotherapeutic treatment (balneotherapy, transcranial magnetic stimulation, transcranial electrical stimulation of endorphin structures of the brain, acupuncture), cognitive training, social and psychological impact. The results of own study of the effectiveness of sensorimotor control of breathing method using the software and hardware complex "DiaTrack-P" based on BFB in the complex correction of respiratory dysfunction and asthenia in the early stages of Parkinson's disease are presented. It was shown that the treatment course of ensorimotor control of breathing based on BFB helps to reduce specific respiratory complaints characteristic of patients with Parkinson's disease, normalizes the biomechanics of breathing with the formation of a normopnoic breathing pattern, reduces autonomic imbalance, manifestations of asthenia, thereby improving the quality of life in patients. CONCLUSION. An integrated approach to the rehabilitation of patients with Parkinson's disease using mainly non- pharmacological methods based on BFB allows to slow down the progression of the disease, achieve long-term treatment effects, reach the desired everyday and socio-cultural adaptation and maintain the quality of life in patients at each stage of the disease.
- 10 September 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (3)
Open AccessNon-pharmacological Rehabilitation Methods for Parkinson's Disease with an Emphasis on Biofeedback Therapy: a Review
INTRODUCTION. Currently, Parkinson's disease is a common socially significant multisystem neurodegeneration that significantly limits the everyday, professional and social activities of patients. The clinical picture includes classic motor symptoms and many non-motor disorders, which requires an integrated approach to treatment. In recent years, it has been paid more attention to the development of rehabilitation for Parkinson's disease, primarily non-pharmacological methods. AIM. To present a literature review on the current use of non-pharmacological methods of treatment and rehabilitation for PD based on biofeedback (BFB). MATERIALS AND METHODS. An analysis of 59 literary sources was conducted on the RSCI and PubMed databases for the period 2010-2025 on the topic of non-pharmacological treatment methods for PD, as well as the use of rehabilitation methods with biofeedback (BFB). Data of our own clinical study are presented. RESULTS AND DISCUSSION. The review considers various options of motor rehabilitation in Parkinson's disease (strength exercises, aerobic training, methods using biofeedback, virtual reality, computer games, mental images), physiotherapeutic treatment (balneotherapy, transcranial magnetic stimulation, transcranial electrical stimulation of endorphin structures of the brain, acupuncture), cognitive training, social and psychological impact. The results of own study of the effectiveness of sensorimotor control of breathing method using the software and hardware complex "DiaTrack-P" based on BFB in the complex correction of respiratory dysfunction and asthenia in the early stages of Parkinson's disease are presented. It was shown that the treatment course of ensorimotor control of breathing based on BFB helps to reduce specific respiratory complaints characteristic of patients with Parkinson's disease, normalizes the biomechanics of breathing with the formation of a normopnoic breathing pattern, reduces autonomic imbalance, manifestations of asthenia, thereby improving the quality of life in patients. CONCLUSION. An integrated approach to the rehabilitation of patients with Parkinson's disease using mainly non- pharmacological methods based on BFB allows to slow down the progression of the disease, achieve long-term treatment effects, reach the desired everyday and socio-cultural adaptation and maintain the quality of life in patients at each stage of the disease.
- 5 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 82-88
On the results of a multicenter, open, observational, non-interventional study of the efficacy and safety of nimesulide (Nise) in combination with muscle relaxants in patients with acute back pain
Objective. To study the efficacy and safety of using Nise and Tolperisone in the treatment of patients with acute low back pain (ALBP). Material and methods. An open observational non-interventional study of the efficacy and safety of Nise (1 tablet of 100 mg in the morning and evening) in combination with the muscle relaxant Tolperisone for 14 days was conducted in patients with acute LBP. The efficacy and safety of using Nise and Tolperisone in patients with acute low back pain was analyzed using a visual analogue pain scale (VAS), the Roland—Morris questionnaire, SPID, the clinical global impression (CGI), and a study of patient diary data. Results. A decrease in pain severity was noted according to the VAS scale, signs of an improvement in functional status were revealed according to the Roland—Morris questionnaire, and high treatment efficacy was revealed according to the patient and doctor according to the CGI questionnaire. Conclusion. The use of Nise and Tolperisone in patients with LBP is effective and safe.
- 5 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 82-88
On the results of a multicenter, open, observational, non-interventional study of the efficacy and safety of nimesulide (Nise) in combination with muscle relaxants in patients with acute back pain
Objective. To study the efficacy and safety of using Nise and Tolperisone in the treatment of patients with acute low back pain (ALBP). Material and methods. An open observational non-interventional study of the efficacy and safety of Nise (1 tablet of 100 mg in the morning and evening) in combination with the muscle relaxant Tolperisone for 14 days was conducted in patients with acute LBP. The efficacy and safety of using Nise and Tolperisone in patients with acute low back pain was analyzed using a visual analogue pain scale (VAS), the Roland—Morris questionnaire, SPID, the clinical global impression (CGI), and a study of patient diary data. Results. A decrease in pain severity was noted according to the VAS scale, signs of an improvement in functional status were revealed according to the Roland—Morris questionnaire, and high treatment efficacy was revealed according to the patient and doctor according to the CGI questionnaire. Conclusion. The use of Nise and Tolperisone in patients with LBP is effective and safe.